Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

clinical benefit

Transitioning to the “New Normal”: What This Means for Oncology Care

Dr. Burt Zweigenhaft, Co-founder of the Association for Value-Based Cancer Care, shares his thoughts on the importance of patient-centricity in cancer care, current barriers to value-based care in the US...

Impetus Digital

Events:

Patient Centricity and Engagement Conference 2021

Research Partnership

- PMLiVE

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’...

Avalere Health

- PMLiVE

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life...

Avalere Health

Realizing the Potential of Genomics-Driven Precision Medicine

Jennifer Helfer, Senior Director, Patient Advocacy & Engagement at Encoded Therapeutics Inc., discusses genomics-driven precision medicine, gene therapy misconceptions and fears, involving patients and caregivers in designing gene therapy trials,...

Impetus Digital

- PMLiVE

Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic

The pandemic has given us a glimpse (actually, more of a very long look) at an alternative way of receiving healthcare and engaging with the NHS. And that alternative fits...

Say Communications

Building Better Patient Advocates Through Authentic Partnerships

Sabrina Hanna, Founder & CIO of the Cancer Collaborative, discusses precision medicine, innovation in oncology, how to build better patient advocates, and the current gaps when it comes to patient-centricity...

Impetus Digital

- PMLiVE

Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO

Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%

- PMLiVE

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

- PMLiVE

US backs proposal to waive IP protection for COVID-19 vaccines

"Monumental decision" could see IP protections for COVID-19 vaccines temporarily removed

How Patient Advocacy Can Positively Disrupt Healthcare

Seth Rotberg, Patient Recruitment Manager at WEGO Health & Co-Founder of Our Odyssey, shares his views on how to empower rare disease patients, improve clinical trials, and move towards a...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links